These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10560800)

  • 1. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage.
    Böhler J; Donauer J; Keller F
    Kidney Int Suppl; 1999 Nov; (72):S24-8. PubMed ID: 10560800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A primer on continuous renal replacement therapy for critically ill patients.
    Joy MS; Matzke GR; Armstrong DK; Marx MA; Zarowitz BJ
    Ann Pharmacother; 1998 Mar; 32(3):362-75. PubMed ID: 9533067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.
    Pea F; Viale P; Pavan F; Furlanut M
    Clin Pharmacokinet; 2007; 46(12):997-1038. PubMed ID: 18027987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effects of dialysate and ultrafiltration flow rate on solute clearance during continuous renal replacement therapy].
    Gong D; Ji D; Xie H; Xu B; Liu Y; Li L
    Zhonghua Nei Ke Za Zhi; 2001 Mar; 40(3):183-6. PubMed ID: 11798577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetic principles and drug-dosing adjustments during continuous renal replacement therapies (CRRT)].
    Morabito S; Guzzo I; Vitaliano E; Muzi L; Solazzo A; Pistolesi V; Pierucci A
    G Ital Nefrol; 2006; 23 Suppl 36():S127-38. PubMed ID: 17068740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRRT efficiency and efficacy in relation to solute size.
    Clark WR; Ronco C
    Kidney Int Suppl; 1999 Nov; (72):S3-7. PubMed ID: 10560796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antimycotic drugs under continuous renal replacement therapy].
    Muhl E
    Mycoses; 2005; 48 Suppl 1():56-60. PubMed ID: 15826289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.
    Reetze-Bonorden P; Böhler J; Keller E
    Clin Pharmacokinet; 1993 May; 24(5):362-79. PubMed ID: 8504621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
    Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients.
    Bugge JF
    Acta Anaesthesiol Scand; 2001 Sep; 45(8):929-34. PubMed ID: 11576041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adsorption and Clearance of the Novel Fluorescent Tracer Agent MB-102 During Continuous Renal Replacement Therapy: In Vitro Results.
    Jang SM; Shieh JJ; Riley IR; Dorshow RB; Mueller BA
    ASAIO J; 2023 Jul; 69(7):702-707. PubMed ID: 37071749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy.
    Weiler S; Seger C; Pfisterer H; Stienecke E; Stippler F; Welte R; Joannidis M; Griesmacher A; Bellmann R
    Antimicrob Agents Chemother; 2013 Aug; 57(8):4053-7. PubMed ID: 23733471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Middle-molecule clearance in CRRT: in vitro convection, diffusion and dialyzer area.
    Messer J; Mulcahy B; Fissell WH
    ASAIO J; 2009; 55(3):224-6. PubMed ID: 19282753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Combined Extracorporeal Life Support and Continuous Renal Replacement Therapy on Hemodynamic Performance and Gaseous Microemboli Handling Ability in a Simulated Neonatal ECLS System.
    Shank KR; Profeta E; Wang S; O'Connor C; Kunselman AR; Woitas K; Myers JL; Ündar A
    Artif Organs; 2018 Apr; 42(4):365-376. PubMed ID: 28940550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous renal replacement therapy does not have a clear role in the treatment of poisoning.
    Kim Z; Goldfarb DS
    Nephron Clin Pract; 2010; 115(1):c1-6. PubMed ID: 20173343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Principles of antibacterial dosing in continuous renal replacement therapy.
    Choi G; Gomersall CD; Tian Q; Joynt GM; Freebairn R; Lipman J
    Crit Care Med; 2009 Jul; 37(7):2268-82. PubMed ID: 19487930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrolyte disorders and substitution fluid in continuous renal replacement therapy.
    Locatelli F; Pontoriero G; Di Filippo S
    Kidney Int Suppl; 1998 May; 66():S151-5. PubMed ID: 9573593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies.
    Hernandez SH; Howland M; Schiano TD; Hoffman RS
    Clin Toxicol (Phila); 2015; 53(10):941-9. PubMed ID: 26484583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal hemodiafilter performance in modeled continuous renal replacement therapy.
    Pasko DA; Churchwell MD; Salama NN; Mueller BA
    Blood Purif; 2011; 32(2):82-8. PubMed ID: 21372565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal replacement therapy III: IHD, CRRT, SLED.
    O'Reilly P; Tolwani A
    Crit Care Clin; 2005 Apr; 21(2):367-78. PubMed ID: 15781169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.